HealthEquity (NASDAQ:HQY – Get Rating) updated its FY 2023 earnings guidance on Tuesday. The company provided earnings per share guidance of $1.23-$1.32 for the period, compared to the consensus earnings per share estimate of $1.28. The company issued revenue guidance of $834.00 million-$844.00 million, compared to the consensus revenue estimate of $831.91 million.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Robert W. Baird lifted their target price on HealthEquity from $47.00 to $67.00 and gave the stock a neutral rating in a research report on Wednesday, September 7th. Raymond James lifted their target price on shares of HealthEquity from $70.00 to $75.00 and gave the company an outperform rating in a research note on Monday, September 12th. The Goldman Sachs Group assumed coverage on shares of HealthEquity in a research report on Tuesday, July 12th. They issued a sell rating and a $59.00 price objective for the company. Wells Fargo & Company boosted their price objective on shares of HealthEquity from $95.00 to $100.00 and gave the stock an overweight rating in a research report on Tuesday, September 13th. Finally, Barrington Research boosted their price objective on shares of HealthEquity from $70.00 to $75.00 in a research report on Tuesday, June 7th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus price target of $75.36.

HealthEquity Trading Down 4.0 %

Shares of HealthEquity stock traded down $2.92 during trading hours on Friday, reaching $70.58. 22,825 shares of the company's stock were exchanged, compared to its average volume of 809,679. The company has a 50 day moving average of $63.03 and a two-hundred day moving average of $62.79. HealthEquity has a fifty-two week low of $36.81 and a fifty-two week high of $74.04. The stock has a market cap of $5.97 billion, a P/E ratio of -96.01, a P/E/G ratio of 4.29 and a beta of 0.90.

Insider Buying and Selling at HealthEquity

In other HealthEquity news, Director Ian Sacks sold 25,000 shares of the stock in a transaction dated Tuesday, September 20th. The shares were sold at an average price of $72.28, for a total value of $1,807,000.00. Following the transaction, the director now directly owns 126,570 shares of the company's stock, valued at approximately $9,148,479.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other HealthEquity news, Director Ian Sacks sold 25,000 shares of the stock in a transaction dated Tuesday, September 20th. The shares were sold at an average price of $72.28, for a total value of $1,807,000.00. Following the transaction, the director now directly owns 126,570 shares of the company's stock, valued at approximately $9,148,479.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Edward Bloomberg sold 1,000 shares of the stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $57.63, for a total transaction of $57,630.00. Following the transaction, the chief operating officer now owns 59,850 shares in the company, valued at approximately $3,449,155.50. The disclosure for this sale can be found here. Insiders own 2.80% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Legal & General Group Plc raised its stake in shares of HealthEquity by 0.7% during the second quarter. Legal & General Group Plc now owns 126,275 shares of the company's stock valued at $7,752,000 after acquiring an additional 844 shares during the last quarter. ExodusPoint Capital Management LP increased its stake in HealthEquity by 410.4% in the second quarter. ExodusPoint Capital Management LP now owns 24,533 shares of the company's stock valued at $1,506,000 after purchasing an additional 19,726 shares in the last quarter. Walleye Capital LLC grew its holdings in shares of HealthEquity by 117.9% during the second quarter. Walleye Capital LLC now owns 12,688 shares of the company's stock valued at $779,000 after buying an additional 6,865 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of HealthEquity by 25.7% during the second quarter. Goldman Sachs Group Inc. now owns 467,225 shares of the company's stock valued at $28,682,000 after buying an additional 95,426 shares during the last quarter. Finally, First Republic Investment Management Inc. boosted its holdings in HealthEquity by 14.5% during the second quarter. First Republic Investment Management Inc. now owns 19,396 shares of the company's stock worth $1,191,000 after purchasing an additional 2,449 shares during the last quarter. Institutional investors and hedge funds own 99.43% of the company's stock.

HealthEquity Company Profile

(Get Rating)

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Featured Articles

• Get a free copy of the StockNews.com research report on HealthEquity (HQY)
• Why Does Tesla Stock Remain Resilient?
• 2 Semiconductor Stocks To Watch For Reversals
• Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
• Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
• Will Crowdstrike Get A Boost From Increased EPS Guidance?

Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.